0 évaluation0% ont trouvé ce document utile (0 vote)
35 vues2 pages
Key performance indicators of the Roche Group Economic and business performance 2009 2008 2007 sales (mCHF) Research and development as % of sales Operating profit before exceptional items Operating profit margin Core earnings per share (mchf) Net financial income (non-voting equity security (genussschein) at 31st of December Dow Jones World and FTSE4good sustainability indexes 175. 151 12% Leader 162. 141 -16.0% Included 195. 171 -9.8% Included 6.00 5,1
Key performance indicators of the Roche Group Economic and business performance 2009 2008 2007 sales (mCHF) Research and development as % of sales Operating profit before exceptional items Operating profit margin Core earnings per share (mchf) Net financial income (non-voting equity security (genussschein) at 31st of December Dow Jones World and FTSE4good sustainability indexes 175. 151 12% Leader 162. 141 -16.0% Included 195. 171 -9.8% Included 6.00 5,1
Droits d'auteur :
Attribution Non-Commercial (BY-NC)
Formats disponibles
Téléchargez comme PDF, TXT ou lisez en ligne sur Scribd
Key performance indicators of the Roche Group Economic and business performance 2009 2008 2007 sales (mCHF) Research and development as % of sales Operating profit before exceptional items Operating profit margin Core earnings per share (mchf) Net financial income (non-voting equity security (genussschein) at 31st of December Dow Jones World and FTSE4good sustainability indexes 175. 151 12% Leader 162. 141 -16.0% Included 195. 171 -9.8% Included 6.00 5,1
Droits d'auteur :
Attribution Non-Commercial (BY-NC)
Formats disponibles
Téléchargez comme PDF, TXT ou lisez en ligne sur Scribd
Research and development (mCHF) 9,874 8,845 8,385 Research and development as % of sales 20.1% 19.4% 18.2% Operating profit before exceptional items (mCHF) 15,012 13,896 14,468 Operating profit margin 30.6% 30.5% 31.4% Net financial income (mCHF) –1,668 236 834 Net Income (mCHF) 8,510 10,844 11,437 Core earnings per share (CHF) 12.19 11.04 11.85 Operating free cash flow 15,722 12,378 10,671 Operating free cash flow as % of sales 32.1% 27.1% 23.1% Net assets (mCHF) 9,414 53,822 53,443 Net cash (debt) (mCHF) –23,867 16,682 17,336 Equity ratio 12.63% 70.70% 68.2%
Increasing value for our shareholders and investors
Dividend per share (CHF) 1) 6.00 5.00 4.60 Dividend (mCHF) 1) 5,175 4,313 3,968 Dividend as % of sales 10.6% 9.5% 8.6% Payout Ratio 53% 49% 41% Price of non-voting equity security (Genussschein) at 31st of December (CHF) 175.80 162.50 195.60 Market capitalization (CHF billions) 151 141 171 Total Shareholder Return (TSR) at 31st of December 12% –16.0% –9.8% Dow Jones World and FTSE4Good sustainability indexes Leader Included Included
Access to healthcare & patients benefits
Number of major regulatory approvals received 13 14 18 Number of major regulatory filings 23 12 14 Patients actively participating in clinical trials 2) 269,895 235,420 201,752 Patients benefiting from Patient Assistance Programs (US only) 40,000 38,000 34,480 Number of phase I—III clinical trials at 31st of December 111 119 108 Number of clinical trial protocols (Phase I—IV) published 649 574 480 % of all HIV/AIDS patients living in countries eligible for no-profit Roche ARV medicines 68% 68% 70% % of all HIV/AIDS patients living in countries eligible for reduced-price Roche ARV medicines 83% 83% 86% Technology Transfer Initiative (TTI) agreements with companies covering sub-Saharan Africa and the least developed countries (LDCs) 13 10 9 2
Commitment to our employees
2009 2008 2007
Number of employees (full-time equivalent — FTE) 81,507 80,080 78,604
Growth in full-time equivalent employees 1,427 1,476 4,232 Total employees’ remuneration (mCHF) 12,080 11,129 10,767 Total employees’ remuneration as % of sales 24.6% 24.4% 23.3% Percentage of women in total workforce 46% 46% 45% Percentage of women in management positions 37% 37% 32% Staff turnover (fluctuation) 7% 9.9% 8.7% Average number of training hours per employee 26 29 34.5 Numbers of Employees on Roche secondment 4 2 3 Pecentage of eligible employees purchased shares through Roche CONNECT 37% 36% 36% Roche’s position in Science magazine’s top employers in the biotech and pharmaceutical industries 17 th 6 th 18 th Genentech’s position in Science magazine’s top employers in the biotech and pharmaceutical industries 1st 1st 2 nd
Commitment to society and the communities we operate in
Income taxes (mCHF) 2870 3,305 3,867 Income taxes as % of sales 5.9% 7.2% 8.4% Community support by area: — Humanitarian and social projects 75% 86% 85.5% — Science and education 17% 11% 11.2% — Arts and culture 5% 2% 1.8% — Community and environment 3% 1% 1.5%
Safety, health and environmental protection
Investments in SHE (mCHF) 159 218 215 Operating costs for SHE (mCHF) 294 295 306 Roche Accident Rate 0.074 0.078 0.076 Occupational accidents 392 474 482 Occupational accidents per million working hours 2.92 3.42 3.46 Occupational illnesses 227 270 311 Eco-Efficiency Rate 84.02 77.95 67.19 eco-balance 4.6 4.95 5.15 Total energy consumption (TJ/year) 13,898 13,662 13,664 Total energy consumption (TJ/year per mCHF sales) 0.283 0.299 0.296 Greenhouse gas emissions (tonnes CO 2 equivalents) 1,053,118 1,062,114 1,052,407 Greenhouse gas emissions (tonnes CO 2 equivalents per mCHF sales) 21.47 23.28 22.81 NO x (t/year) 286 193 169 SO2 (t/year) 9 10 12 Volatile organic compounds (VOCs) (t/year) 177 213 240 Particulate matter (t/year) 27 27 25 Water consumption (million cubic meters per year) 2.8 2.4 2.30 Water consumption (cubic meters per year per mCHF sales) 56.12 51.9 50.3 Total organic carbon (TOC) (t/year) 154 592 641 Heavy metals (kg/year) 426 545 605 Chemical waste (t/year) 27,605 31,295 38,167 General waste (t/year) 19,828 42,823 17,480
1) For the year 2009 as proposed by the Board of Directors
2) Development phases I to IV Figures for 2007 as in Annual Report 2008 n. a. = not available n. i. = not yet initiated